Results 191 to 200 of about 12,649 (233)
Some of the next articles are maybe not open access.

LEUKOTRIENES, LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA: AN UPDATE. PART II: CLINICAL STUDIES WITH LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN ASTHMA

Pharmacological Research, 1999
The demonstration that leukotrienes, mainly cysteinyl leukotrienes, have biological properties relevant to the pathogenesis of asthma has stimulated the development of many therapeutic compounds to block these deleterious effects. Two main classes of leukotriene modulators have been developed: CysLT1 receptor antagonists and leukotriene synthesis ...
P, Devillier, N, Baccard, C, Advenier
openaire   +2 more sources

Challenge Studies of a Leukotriene Receptor Antagonist

Chest, 1997
The leukotriene receptor antagonist pranlukast (SB 205312, ONO-1078) has demonstrated clinical activity as an antiasthma drug in traditional challenge models, including exercise-induced asthma and inhaled bronchoprovocations with sulpyrine (an aspirin analogue), antigen, methacholine, leukotriene C4, and leukotriene D4. This article reviews the results
openaire   +2 more sources

Leukotriene receptor antagonists in the treatment of asthma: an update

Allergy, 2002
Leukotriene receptor antagonists (LTRAs), such as montelukast and zafirlukast, have been demonstrated in a number of studies to possess bronchodilating and anti‐inflammatory properties, that make these drugs ideal candidates for the treatment of asthma. The last 1998‐updating of the GINA Guidelines for the diagnosis and therapy of asthma recommends the
G, Balzano, S, Fuschillo, C, Gaudiosi
openaire   +2 more sources

Leukotriene Receptor Antagonists as Potential Therapeutic Agents

Annual Review of Pharmacology and Toxicology, 1989
Leukotrienes are a family of bioactive lipids that have a constellation of pharmacologic effects on respiratory, cardiovascular, and gastrointestinal systems. They produce smooth muscle spasm (1, 2), cause myocardial de­ pression (3), increase vascular permeability ( l , 4) enhance mucous produc­ tion (5), decrease mucociliary transport (6), and have ...
D W, Snyder, J H, Fleisch
openaire   +2 more sources

Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma

Allergy, 2001
Cysteinyl leukotrienes, synthesized de novo from cell membrane phospholipids, are proinflammatory mediators that play an important role in the pathophysiology of asthma. These mediators are among the most potent of bronchoconstrictors and cause vasodilation, increased microvascular permeability, exudation of macromolecules and edema.
openaire   +2 more sources

Role of leukotriene receptor antagonists in pediatric asthma

Pediatric Pulmonology, 2000
During the past decade, the inflammatory mechanisms that result in the clinical syndrome we call asthma have been emphasized in research, publications, and the various asthma management guidelines. This information clearly emphasizes the treatment of asthma with maintenance controller therapies early after the onset of symptoms in all but the very ...
openaire   +2 more sources

Role of Leukotrienes and Leukotriene Receptor Antagonists in Asthma

Pulmonary Pharmacology & Therapeutics, 1999
T R, Jones, I W, Rodger
openaire   +2 more sources

Leukotriene Receptor Antagonists

2022
Rui Zheng, Tian Yuan, Qintai Yang
openaire   +1 more source

Leukotriene receptor antagonists. III. Pharmacological and chemical studies with LY137617, a leukotriene D4 and leukotriene E4 receptor antagonist.

Drugs under experimental and clinical research, 1989
A series of chlorophenoxyalkyl acids were prepared and evaluated as pharmacological antagonists of leukotriene D4. Structure-activity relationship studies pointed to LY137617 as a compound with possible therapeutic value. In experiments on isolated smooth muscles from the guinea-pig, this agent was a selective and moderately potent antagonist of ...
D K, Herron   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy